Abstract

The article published in the December 2021 issue

(Acta Myologica • 2021;XL(4):152-157. https://doi.org/10.36185/2532-1900-058)

Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up

Amir Dori, Michela Guglieri, Marianna Scutifero, Luigia Passamano, Antonio Trabacca, Luisa Politano

has been withdrawn upon request of the authors.

Authors

Amir Dori - Department of Neurology, Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Tel HaShomer, and Joseph Sagol Neuroscience Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Michela Guglieri - John Walton Muscular Dystrophy Research Centre, Newcastle University, United Kingdom

Marianna Scutifero - Cardiomyology and Medical Genetics, University of Campania “Luigi Vanvitelli”, Naples, Italy

Luigia Passamano - Cardiomyology and Medical Genetics, University of Campania “Luigi Vanvitelli”, Naples, Italy

Luigi Trabacca - Unit for serious disabilities of developmental and young adult age, Developmental Neurology and Neurorehabilitation, IRCCS “E. Medea” - “Our Family” Association, Brindisi, Italy

Luisa Politano -  Cardiomyology and Medical Genetics, University of Campania “Luigi Vanvitelli”, Naples, Italy; “G. Torre” Association for Muscular Dystrophies Research Unit, Naples, Italy

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright

Copyright (c) 2022 Acta Myologica

How to Cite
Dori, A., Guglieri, M., Scutifero, M., Passamano, L., Trabacca, L., & Politano, L. (2022). Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up. Acta Myologica, 41(1). Retrieved from https://www.actamyologica.it/article/view/435
  • Abstract viewed - 10 times